The Question Appears to Be Based on a Misunderstanding
There is no recent CDC recommendation to extend oral artemisinin-based combination therapy (ACT) to 5 days for uncomplicated malaria, and therefore WHO has had no reason to comment on such a position. The standard treatment duration for ACTs remains 3 days globally, as recommended by both WHO and CDC.
What Actually Exists: The Swiss 5-Day Regimen
The confusion likely stems from Swiss national guidelines, not CDC recommendations. Switzerland has recommended extending artemether-lumefantrine (AL) treatment from the standard 3-day regimen (6 doses) to 5 days (adding 4 additional doses) for specific patients 1. This Swiss-specific recommendation was made due to:
- Treatment failures observed in European settings with standard 3-day AL regimens 1
- Body weight effects on lumefantrine therapeutic concentrations, which may be responsible for therapeutic failure 1
- Possible malabsorption issues in certain patient populations 1
Importantly, most European treatment failures with ACTs have not demonstrated the pfk13 mutations associated with artemisinin resistance (with the notable exception of recent Belgian case series) 1.
Current Global Standard Remains 3 Days
Both WHO and CDC continue to endorse standard 3-day ACT regimens for uncomplicated malaria 2. The evidence provided shows:
- CDC's 2018 guidelines focus on expanding AL use to pregnant women (all trimesters), not extending treatment duration 2
- The 2024 European guidelines confirm standard 3-day ACT treatment remains the norm, with only Switzerland as an outlier recommending 5-day extension 1
- WHO continues to recommend ACTs as first-line therapy with standard dosing 1, 3, 4
Why WHO Hasn't Responded
WHO has no need to comment because:
- This is a single-country (Swiss) guideline, not a CDC position
- National guidelines can vary based on local epidemiology and treatment failure patterns
- The Swiss recommendation is pragmatic for their specific context of imported malaria cases with observed treatment failures
- It doesn't contradict WHO recommendations—it's an extension for specific circumstances, not a replacement of the standard regimen
Clinical Implications
For practicing clinicians treating uncomplicated malaria:
- Use standard 3-day ACT regimens (artemether-lumefantrine 6 doses over 3 days, or other ACTs per standard protocols) 1
- Consider extended regimens (5-day AL) only in specific circumstances:
- Patients with high body weight where lumefantrine levels may be subtherapeutic
- Previous treatment failure with standard regimen
- Possible malabsorption issues
- Monitor for treatment failure with parasitemia checks at 12-hour intervals until <1%, then daily until negative 1
- Be aware of emerging artemisinin resistance in East Africa (Rwanda, Uganda, Tanzania, Ethiopia, Eritrea) where pfk13 mutations are now established 5
The evidence does not support a CDC recommendation for routine 5-day ACT treatment, and WHO's silence reflects the absence of such a recommendation requiring response.